2021 annual financial data

Inhibikase Therapeutics 2021 Net margin

Direct answer

Net margin was -477.52%.

Operating income was -14.77M USD and net income was -14.81M USD.
Operating cash flow was -14.3M USD.

Get free Inhibikase Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
3.1M USD
Operating income
-14.77M USD
Net income
-14.81M USD
Operating cash flow
-14.3M USD